News | Pacemakers | February 20, 2019

Medtronic Recalls Dual Chamber Pacemakers

Class I recall identifies possible circuit error that can result in a lack of pacing

Medtronic Recalls Dual Chamber Pacemakers

February 20, 2019 — Medtronic is recalling its dual chamber implantable pulse generators (IPGs) due to the possibility of a software error that can result in a lack of pacing. Patients and physicians cannot predict whether and when this software error might occur. A lack of pacing could result in patients experiencing slow heart beating, low blood pressure, and symptoms such as light headedness, fainting and even death.

Medtronic’s dual chamber IPGs are implanted cardiac pacemakers used to provide stimulation to increase heart rate in patients with a slow heart rhythm (bradycardia) or no heart rhythm. The pulse generator is the small implanted unit containing the battery and other electronic parts. The pulse generator must be used with insulated electrode wires called leads. These devices are designed to be used in addition to routine clinical monitoring by a healthcare professional.

The recall impacts Medtronic’s Adapta, Versa, Sensia, Relia, Attesta, Sphera and Vitatron A, E, G and Q series IPGs. All affected products were manufactured between March 2, 2017, and Dec. 18, 2018; they were distributed between March 6, 2017, and Jan. 7, 2019. A total of 13,440 devices have been recalled in the U.S.

Beginning Jan. 17, 2019, Medtronic’s field representatives have hand-delivered “Field Corrective Action Notification” letters to implanting and follow-up physicians.

For healthcare providers:

  • Medtronic recommends programming to a non-susceptible pacing mode as the primary mitigation for patients implanted with an affected device until the software update has been installed;
  • Additional patient risk assessment and programming recommendations are included in Medtronic’s advisory letter;
  • In addition to the field correction notification, Medtronic’s field representatives will:
    • Hand-deliver an additional “Supplemental Letter” alongside an “Urgent Medical Device Recall” letter to physicians with patients whose devices have shown evidence of a pacing pause that may be related to this circuit error;
    • Request physicians return all unused and unopened affected product to Medtronic for replacement;
    • Confirm notifications are received by implanting or follow-up physicians using Medtronic’s electronic tracking system in conjunction with confirmation via a paper form; and
    • Conduct effectiveness checks to ensure that all identified implanting or follow-up physicians and risk managers have been notified or proof of at least three attempts to notify them is obtained.

The letter recommends that patients remaining in a susceptible mode should seek immediate medical attention if experiencing any new or unexpected symptoms consistent with a pause in pacing.

Customers who have questions or need additional information regarding this recall may contact Medtronic’s Technical Services at 1-800-505-4636.

Healthcare professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Healthcare professionals employed by facilities that are subject to FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.

For more information: www.medtronic.com

Related Content

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing car
A comparison between the EPstar 2F and 6F catheters from Baylis. Electrophysiology catheters. EP lab

A comparison between the EPstar 2F and 6F catheters from Baylis.

News | EP Lab | October 31, 2019
October 31, 2019 — Baylis Medical announced the first North American use of its EPstar Fixed...
New Study Shows Chronic Epilepsy Associated With Marker of Cardiac Electrical Instability
News | EP Lab | October 24, 2019
LivaNova PLC announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be...
Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Overlay Init